Impressive RNS30 Jun 2025 12:46
You may have seen the RNS released this morning congratulating HVO client, Cidara Therapeutics for their positive topline results from their Phase 2b field study, for which hVIVO recruited participants and performed the virology and immunology laboratory services. The study was to determine the efficacy of Cidara’s drug-Fc conjugate, CD388, which is designed as a non-vaccine preventative of seasonal influenza.
Not only was hVIVO awarded their largest field study contract supporting a new income stream, but hVIVO was also selected as the sole UK site for the field study and achieved a total of 817 healthy participants via the Company’s dedicated volunteer recruitment arm, FluCamp.
Further to this, hVIVO’s laboratory, hLAB, was selected as the sole virology laboratory for this international, multi-site Phase 2b field study to conduct the comprehensive virology and immunology analysis for the 61 study sites and approximately 5,000 participants worldwide. This was hLAB’s largest contract to date, following its launch as a standalone service in September 2024.
The positive results of the study further solidifies that HVO can deliver on our diversification of services strategy, in addition to our human challenge trial work. These services support the Group's 'optimise, scale and diversify' growth strategy, by leveraging our existing infrastructure and staff to provide a high-margin new revenue stream.
Sign In
Follow the stocks
